 Comparative effects APSAC rt-PA infarct size ventricular function acute myocardial infarction multicenter study BACKGROUND Recombinant tissue-type plasminogen activator rt-PA alteplase plasminogen streptokinase activator complex APSAC anistreplase infarct size left ventricular function acute myocardial infarction efficacy safety thrombolytic agents trial aim study METHODS RESULTS eighty-three patients first acute myocardial infarction APSAC units minutes single-chain rt-PA mg period hours onset symptoms Global regional left ventricular function contrast angiography average days initial therapy Radionuclide angiography single-photon emission tomography hospital discharge Infarct size single-photon emission tomography percentage total myocardial volume Ninety patients APSAC rt-PA mean period minutes onset symptoms groups similar age location acute myocardial infarction Killip class time randomization patency rate infarct-related artery APSAC group rt-PA group NS Initial predischarge ventricular ejection fraction infarct size similar therapeutic groups versus initial versus predischarge ejection fraction versus infarct size APSAC- rt-PA-treated patients complications blood transfusion APSAC patient rt-PA patients patient rt-PA group massive intracranial hemorrhage end follow-up period APSAC patients rt-PA patients CONCLUSIONS early infusion APSAC rt-PA acute myocardial infarction similar patency rate limitation infarct size preservation left ventricular systolic function equivalent rate complications